OncoMatch/Clinical Trials/NCT05384821
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
Is NCT05384821 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for wilms tumor.
Treatment: Vincristine · Irinotecan · Temozolomide · Etoposide · Cis-Retinoic acid — This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: chemotherapy
After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for which there would not be any curative therapy. If 1 line for high risk relapse, the enrolment should be confirmed by coordinators.
Cannot have received: chemotherapy or radiotherapy of target lesion
Chemotherapy or radiotherapy of target lesion within 3 weeks prior to inclusion
Cannot have received: target therapy
Target therapy within less than 5 * half-life of the substance prior to inclusion
Lab requirements
Blood counts
Neutrophils > 1000/mm3; Platelets > 75,000/mm3
Kidney function
Creatinine ≤ 1.5 ULN or clearance ≥ 60 mL/min/1.73m2 (In case of doubt, to be confirm by assessment of cystatin)
Liver function
Transaminases (ALT/AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease)
Adequate biological criteria: Neutrophils > 1000/mm3; Platelets > 75,000/mm3; Transaminases (ALT/AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease); Creatinine ≤ 1.5 ULN or clearance ≥ 60 mL/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify